Wednesday, 17 Oct 2018

You are here

EMA to Review Methotrexate Overdose and Dosing Errors

A recent meeting (April 9-12) of the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) considered the problem of dosing errors with methotrexate (MTX), citing "continued reports of overdose." 

Although usually dosed at low doses,  given weekly (for rheumatoid arthritis; higher in some malignancies), the EMA has noted reports of improper MTX dosing that has lead to fatal or serious outcomes in some reports. Prompted by the Spanish medicines regulator, AEMPS, the PRAC was asked to investigate why dosing errors continue with MTX.  

There has been sporadic reports of MTX dosing errors for years, but the EMA notes that measures to reduce this risk are unclear.

Medscape reports that the PRAC will examine the evidence and make recommendations to the Committee for Medicinal Products for Human Use, on how to minimize this risk. (Citation souce:  https://wb.md/2H2Et46)

Severe toxicity from MTX may include mucosal or gastrointestinal tract ulceration, liver toxicity, bone marrow suppression, septicemia, or death.  Risk factors for MTX overdose/toxicity typically include renal insufficiency (or sudden decline in renal function), hypoalbuminemia, dosing errors (use of higher than recommended doses) and failure to use folate supplementation.

Several recent reports underscore the serious consequences of rarely seen MTX dosing errors. 

  • Ajmani et al reported on 46 cases of MTX induced severe pancytopenia observed over a 19 year period. They noted a high mortality rate (13/46) and that the presenting symptoms may be high fever and severe mucositis. Common features included: oral mucositis (n = 37); fever (24); diarrhea (12), bleeding gums (5) and purpura (3). http://bit.ly/2JLjXa5 
  • A study of 4 different Danish registers identified 173 errors with nearly two-thirds resulting in harm. Serious harm occurred in 15% and there were 9 deaths (5%). These involved involved incorrect daily administration (31%), dosing errors (62%) and 9% had improper \monitoring. Prescription errors involving daily rather than weekly administration, by hospital physicians, were most likely to result in serious outcomes, including deaths. http://bit.ly/2JLlxZz
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.

New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis

The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.

It addresses safety recommendations for all biologic therapies approved by the National Institute for Health and Care Excellence (NICE) up to June 2016, for use in all inflammatory arthritides [RA, PsA and axial SpA (SpA) including AS].

The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination

The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP). 

Health Secretary Azar Eyes Rebate Reform

Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.

Azar has said rebates created a perverse incentive to continuously raise drug prices.